X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Acadia will acquire ex-North American rights to the drug as well as global rights in Rett syndrome and Fragile X syndrome to Neuren’s development candidate NNZ-2591, an investigational synthetic analogue of cGP, for Rett syndrome and Fragile X syndrome.
Lead Product(s): Cyclo-Glycyl-proline Analog
Therapeutic Area: Genetic Disease Product Name: NNZ-2591
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Acadia Pharmaceuticals
Deal Size: $463.0 million Upfront Cash: $100.0 million
Deal Type: Licensing Agreement July 13, 2023
Details:
NNZ-2591 has ideal attributes – a unique mechanism of action, consistent and compelling results in the model of each disorder, a clearly identified optimum dose and proprietary manufacturing with high purity and yield.
Lead Product(s): Pyrrolo(1,2-a)pyrazine-1,4-dione, hexahydro-8a-(2-propenyl)-, (8aR)-
Therapeutic Area: Genetic Disease Product Name: NNZ-2591
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
